TG Therapeutics (TGTX)
(Delayed Data from NSDQ)
$24.65 USD
-0.63 (-2.49%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $24.64 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Balance Sheet
Fiscal Year End for TG Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 218 | 162 | 315 | 605 | 140 |
Receivables | 51 | 0 | 1 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 40 | 0 | 0 | 0 | 0 |
Other Current Assets | 10 | 7 | 15 | 6 | 9 |
Total Current Assets | 318 | 168 | 331 | 612 | 149 |
Net Property & Equipment | 0 | 0 | 1 | 0 | 0 |
Investments & Advances | 0 | 12 | 36 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 1 | 1 | 1 | 1 | 1 |
Deposits & Other Assets | 3 | 3 | 3 | 3 | 3 |
Total Assets | 330 | 194 | 380 | 626 | 163 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 1 | 0 | 0 |
Accounts Payable | 38 | 42 | 51 | 37 | 30 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 22 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 12 | 8 | 10 | 8 | 4 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 1 | 2 | 18 | 49 |
Total Current Liabilities | 54 | 53 | 65 | 88 | 84 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 6 | 0 | 0 | 1 | 1 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 100 | 71 | 67 | 8 | 29 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 169 | 135 | 142 | 106 | 124 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,675 | 1,586 | 1,566 | 1,500 | 740 |
Retained Earnings | -1,514 | -1,527 | -1,329 | -981 | -701 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 161 | 59 | 237 | 519 | 39 |
Total Liabilities & Shareholder's Equity | 330 | 194 | 380 | 626 | 163 |
Total Common Equity | 161 | 59 | 237 | 519 | 39 |
Shares Outstanding | 151.40 | 145.30 | 141.40 | 131.40 | 99.50 |
Book Value Per Share | 1.06 | 0.40 | 1.68 | 3.95 | 0.39 |
Fiscal Year End for TG Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 217 | 210 | 218 | 229 | 145 |
Receivables | 84 | 65 | 51 | 39 | 17 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 81 | 78 | 40 | 34 | 30 |
Other Current Assets | 7 | 8 | 10 | 17 | 16 |
Total Current Assets | 389 | 361 | 318 | 319 | 209 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 1 | 1 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 1 | 1 | 1 | 1 |
Deposits & Other Assets | 3 | 3 | 3 | 3 | 3 |
Total Assets | 401 | 373 | 330 | 331 | 221 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 93 | 87 | 38 | 40 | 63 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 6 | 4 | 12 | 8 | 7 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 8 | 7 | 2 | 8 | 2 |
Total Current Liabilities | 109 | 100 | 54 | 58 | 73 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 4 | 3 | 6 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 103 | 101 | 100 | 99 | 98 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 224 | 213 | 169 | 166 | 180 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,734 | 1,685 | 1,675 | 1,665 | 1,654 |
Retained Earnings | -1,556 | -1,525 | -1,514 | -1,500 | -1,614 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 178 | 160 | 161 | 165 | 40 |
Total Liabilities & Shareholder's Equity | 401 | 373 | 330 | 331 | 221 |
Total Common Equity | 178 | 160 | 161 | 165 | 40 |
Shares Outstanding | 154.50 | 154.50 | 151.40 | 150.90 | 149.40 |
Book Value Per Share | 1.15 | 1.04 | 1.06 | 1.09 | 0.27 |